AKESO(09926),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

09926 AKESO

Market Closed 12-05 16:09:08

124.100

+0.700

+0.57%

High125.400	Low121.300	Vol3.90M
Open123.500	D1 Closing123.400	Amplitude3.32%
Mkt Cap114.30B	Tradable Cap114.30B	Total Shares921.00M
T/O480.65M	T/O Rate0.42%	Tradable Shares921.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"09926","market":"HK","secType":"STK","nameCN":"AKESO","latestPrice":124.1,"timestamp":1764922148009,"preClose":123.4,"halted":0,"volume":3902670,"delay":0,"floatShares":921000000,"shares":921000000,"eps":-0.6658561649539912,"marketStatus":"Market Closed","change":0.7,"latestTime":"12-05 16:09:08","open":123.5,"high":125.4,"low":121.3,"amount":480653026,"amplitude":0.033225,"askPrice":124.1,"askSize":18000,"bidPrice":123.8,"bidSize":19000,"shortable":3,"etf":0,"ttmEps":-1.0646048652046645,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":7,"adr":0,"listingDate":1587657600000,"exchange":"SEHK","adjPreClose":123.4,"openAndCloseTimeList":[[1764898200000,1764907200000],[1764910800000,1764921600000]],"volumeRatio":0.977391080276078,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09926","defaultTab":"news","newsList":[{"id":"1146416783","title":"Akeso, Inc. (09926) Announces Monthly Return for November 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1146416783","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146416783?lang=en_us&edition=fundamental","pubTime":"2025-12-04 16:49","pubTimestamp":1764838157,"startTime":"0","endTime":"0","summary":"Akeso, Inc. (Stock Code: 09926) submitted its monthly return for the period ended 30 November 2025. According to the announcement, the company’s authorized share capital remains at 5,000,000,000...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"gpt_icon":0},{"id":"1134728285","title":"10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled","url":"https://stock-news.laohu8.com/highlight/detail?id=1134728285","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134728285?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:38","pubTimestamp":1764761917,"startTime":"0","endTime":"0","summary":"On December 3, 2025, the \"10th Zhitong Capital Market Annual Conference & Listed Companies Awards Ceremony,\" jointly hosted by leading Hong Kong and U.S. stock information platform Zhitong Finance...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171","01070","IE00BVYPNQ40.USD","LU1224709979.USD","LU0084288322.USD","LU0214875030.USD","LU1226288170.HKD","BK1552","HK0000165453.HKD","LU0348825331.USD","BK1220","BK1617","09956","SG9999015945.SGD","HK0000500386.USD","BK1229","BK1541","LU0640798160.USD","SG9999001903.USD","BK1188","02105","BK1571","BK1575","06913","BK1618","BK1224","LU0516423174.USD","LU0588546209.SGD","LU2097828714.EUR","00798","LU1960683339.HKD","LU1770034418.SGD","02886","LU0501845795.SGD","09860","02453","LU0269904917.USD","IE0034224299.USD","BK1179","LU1868837565.USD","LU2294711713.HKD","09911","BK1207","BK1596","LU2663582299.SGD","LU2153592121.USD","LU0588545730.USD","02250","BK1539","LU0828237510.HKD","IE00B8L5B284.USD","02451","LU0540923850.HKD","02150","01952","BK1237","01880","06963","BK1163","LU0708995583.HKD","IE0032431581.USD","BK1147","BK1209","BK1140","80020","09699","LU2242644610.SGD","06988","LU0165289439.USD","IE00BGHQDM52.EUR","BK1190","06168","LU0588545904.SGD","LU2328871848.SGD","01471","02627","BK1582","LU0505663152.USD","LU0348767384.USD","LU1282649067.USD","LU0228659784.USD","02197","BK1119","02552","LU0072462343.USD","LU0072913022.USD","BK1600","03681","LU2097828474.EUR","BK1164","LU1634259557.SGD","LU0791590937.USD","LU1951186391.HKD","06100","LU0856984785.SGD","SG9999000475.SGD","HK0000306701.USD","02511","LU2153591404.USD","02331","03998","BK1111","03800","06996","LU0594300179.USD","01739","00017","02018","BK1143","LU0417516902.SGD","LU1868838027.USD","LU2449936058.SGD","LU0082770016.SGD","LU1719994722.HKD","82331","LU0011963245.USD","LU1282649810.SGD","01117","09660","BK1555","BK1608","LU0823437842.USD","01520","00020","IE0009570106.USD","03738","02431","LU0052756011.USD","02551","BK1594","02598","BK1592","06069","02509","LU0702159699.USD","HK0000306685.HKD","BK1240","LU1861214812.USD","LU0051755006.USD","LU1226287792.SGD","BK1096","LU1497733557.USD","02506","BK1109","BK1168","BK1200","IE0003795394.USD","LU0149721374.USD","LU0572939691.SGD","IE00B29SXG58.USD","LU0107464264.USD","LU0261950470.USD","00992","LU0315179316.USD","LU1956131251.USD","BK1134","LU0823039010.USD","LU3063872942.SGD","09690","01585","06086","03677","LU0054450605.USD","LU0251144936.SGD","IE00B543WZ88.USD","BK1155","LU0588545490.SGD","SG9999006597.SGD","BK1184","LU0828238088.HKD","BK1559","BK1170","BK1171","BK1158","BK1127","LU0359201885.HKD","BK1557","03896","01530","LU2045819591.USD","03939","03709","LU0082770016.USD","LU2348774022.SGD","BK1258","BK1553","BK1587","SG9999001093.SGD","LU0516422952.EUR","BK1139","SG9999004311.SGD","BK1154","02858","09961","BK1586","LU0593848301.USD","LU1303224171.USD","LU0348805143.USD","LU0164872284.USD","00884","LU2097828805.USD","LU1974910355.USD","LU0469268626.HKD","09990","LU0348783233.USD","IE00BGV7N243.SGD","BK1598","LU0541501648.USD","LU0831093199.SGD","BK1175","BK1588","06160","09639","SG9999001226.SGD","BK1527","06060","BK1521","BK1136","06677","HK0000252160.HKD","00460","02155","LU0499858438.USD","02158","BK1128","02595","02276","02488","LU1226288253.USD","01877","LU0289961442.SGD","BK1610","LU0289739343.SGD","02392","BK1583","LU1634259391.SGD","06919","IE00BYV24P56.USD","LU1166156734.SGD","00960","LU0164865239.USD","BK1564","LU1328277881.USD","02436","BK1132","BK1516","BK1593","00999","02013","BK1216","IE0031814852.USD","82020","SGXZ86797644.SGD","LU1880383440.USD","BK1589","LU0348827113.USD","BK1549","06609","LU1328615791.USD","02565","LU0384037296.USD","LU1807302812.USD","SGXZ62798434.SGD","LU0329678170.USD","02590","06608","LU0259732245.USD","LU1831875114.USD","06058","LU1868837722.USD","BK1126","LU0823426480.USD","LU1508157978.USD","06633","IE00B8HQ1Z84.USD","LU0868486357.SGD","LU1770036033.HKD","BK1579","BK1222","02279","LU2348773727.SGD","06821","LU2238339852.HKD","BK1239","LU0531971595.HKD","BK1526","LU0865486749.SGD","LU0048597586.USD","09878","01384","BK1504","LU0456846285.SGD","LU1522347837.USD","06186","02420","06657","00666","06855","LU0791591158.USD","SGXZ90724238.SGD","LU0039217434.USD","LU0067412154.USD","LU2097828557.USD","LU0370786039.SGD","BK1530","09985","LU1366334651.USD","LU0605514214.HKD","LU1008478684.HKD","LU0143863198.USD","LU0650527681.SGD","BK1144","BK1227","LU0823038988.USD","00777","02298","01907","BK1186","SG9999014674.SGD","BK1604","81211","LU2399975544.HKD","BK1619","SG9999001069.SGD","02889","03396","06683","LU0359202008.SGD","BK1528","SG9999015978.USD","01833","01735","00855","BK1616","BK1194","01318","BK1114","BK1544","LU1861219969.SGD","BK1100","LU1267930227.SGD","LU2106854487.HKD","LU1152091168.USD","LU0737861699.HKD","09996","LU0261947096.USD","02190","IE00BD6J9T35.USD","LU0329678337.USD","LU2249611893.SGD","00826","BK1531","02315","BK1548","LU0348766576.USD","LU1366334578.USD","01211","BK1590","LU1939255532.USD","02177","09959","IE00BZ08YT58.USD","02696","BK1212","BK1148","LU0054237671.USD","LU0173614495.USD","LU0509642566.USD","SG9999006514.SGD","00136","02145","BK1524","00512","09890","LU0140636845.USD","LU0634319403.HKD","03836","06613","LU1211504680.USD","09880","LU0211977185.USD","LU0345776255.USD","02556","LU1497734951.SGD","02400","02616","LU0823414551.USD","BK1523","LU2476274308.USD","00363","BK1560","BK1502","LU0274383008.USD","LU0531970944.HKD","LU0314109678.HKD","BK1578","LU2424517915.HKD","BK1509","IE00B031HY20.USD","01969","BK1606","LU0543330566.HKD","BK1110","LU1188198961.HKD","LU0175139822.USD","LU0345775950.USD","02650","LU0229945570.USD","LU1242518857.USD","LU2360107325.USD","LU0417516738.SGD","LU2125910500.SGD","LU0871576103.HKD","LU2506952253.HKD","LU1675838814.USD","00003","SG9999015986.USD","BK1169","03658","LU0541502299.USD","02057","BK1522","03680","01762","SG9999002463.SGD","09992","LU0287142896.SGD","LU0326950275.SGD","IE00BQXX3C00.GBP","LU0307460666.USD","BK1556","BK1233","LU0819121731.USD","HYDD.SI","LU0449515922.USD","LU0561508036.HKD","LU0463099449.HKD","LU1794554557.SGD","02273","LU1961090484.USD","02567","BK1214","09927","02629","LU2506951792.HKD","BK1215","LU0128525689.USD","LU1115378108.SGD","LU0348735423.USD","01440","LU0049112450.USD","06138","09926","09919","BK1125","LU2778985437.USD","01651","BK1183","LU0244354667.USD","IE00B5MMRT66.SGD","LU0327786744.USD","02268","LU1102505762.USD","LU1993786604.SGD","LU2357125470.USD","LU0737861772.HKD","LU0516422366.SGD","03650","LU0456827905.SGD","BK1577","LU0417516571.SGD","02020","IE0008368742.USD","LU0348784397.USD","LU0511384066.AUD","BK1198","HK0000320223.HKD","01809","BK1566","IE00BVYPNP33.GBP","BK1253","IE00B0JY6N72.USD","LU1808992512.USD","01333","BK1597","00384","BK1247","BK1615","BK1607","01773","06862","BK1609","BK1225","LU0819123356.HKD","LU1048588211.SGD","01276","00656","09678","BYDDY","02525","BK1512","LU1981816686.USD","BK1221","BK1595","LU1497733631.SGD","02121","LU0315178854.USD","LU0823397103.USD","LU0516423091.SGD","IE0008369823.USD","LU0979878070.USD","IE00B031J352.USD","BK1104","00699","LU0264606111.USD","01939","LU0289960550.SGD","LU0572940350.SGD","BK1219","02533","BK1195","BK1515","LU0880133367.SGD","00300","BK1160","LU2543165471.USD","LU0611395673.USD","BK1124","BK1197","09877","BK1142","LU0320764599.SGD","00302","LU0823426308.USD","BK1585","LU0572944931.SGD","BK1116","LU1813983027.USD","LU0231483743.USD","LU1917777945.USD","LU2177674079.SGD","IE00BPRC5H50.USD","LU1242518931.SGD","LU1023057109.AUD","IE00BQXX3F31.USD","02256","BK1550","LU2039709279.SGD","SG9999002828.SGD","02411","LU2476274720.SGD","LNVGY","LU0502904849.HKD","00382","HK0000320264.USD","IE00BZ08YS42.EUR","09923","00861","01119","IE0003851619.USD","01600","BK1137","BK1574","02460","LU1720050803.USD","BK1605","02670","002594","LU2008162690.USD","LU0488056044.USD","LU0823414478.USD","LU0455707207.USD","BK1520","LU0043850808.USD","LNNGY","HK0000252152.HKD","09955","BK1542","02096","SG9999000418.SGD","BK1095","LU0251143458.SGD","ANPDY","LU1226287875.USD","SG9999004220.SGD","SG9999003461.SGD","LU0143863784.USD","01640","BK1151","BK1193","BK1500","SG9999000459.SGD","01405","02100","BK1613","BK1257","BK1228","IE00BMCWC346.EUR","01458","LU2023250504.SGD","01519","LU0762540952.USD","LU1102505929.USD","BK1519","BK1141","IE00BZ08YR35.GBP","LU0164939612.USD","LU0516422440.USD","09636","SG9999001051.SGD","LU0164880469.USD","LU2097828631.EUR","LU1039395188.USD","LU0499858602.USD","01783","01378","01177","LU0823397285.USD","00875","01093","02382","LU1235295612.USD","01911","LU0431992006.USD","06618","80992","LU0449509016.USD","BK1131","86618","BK1117","01818","BK1518","SG9999002950.SGD","02380","BK1235","02419","02587","BK1540","IE00BQXX3D17.EUR","BK1167","BK1178","LU1880383366.USD","00867","LU0254981946.USD","02228","01164","00135","SG9999015952.SGD","BK1189","LU1969619763.USD","LU0359201612.USD","BK1150","LU0048575426.USD","BK1591","BK1230","LU0620787316.HKD","02498","BK1554","SG9999002562.SGD","00267","LU0052750758.USD","LU2488822045.USD","LU0310800965.SGD","LU1046422090.SGD","LU2298064838.USD","LU1251922891.USD","LU0261950983.USD","02157","01681","03145","LU1152091754.HKD","02469","06090","02142","BK1161","LU1481107354.HKD","01448","LU0594300419.USD","LU2460026573.USD","SG9999011746.SGD","00305","00451","LU0048580855.USD","02167","BK1191","LU1226287529.USD","IE00B0169L03.USD"],"gpt_icon":1},{"id":"2588251016","title":"Asian Value Stocks Estimated At 15.2% To 40.3% Below Intrinsic Worth","url":"https://stock-news.laohu8.com/highlight/detail?id=2588251016","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588251016?lang=en_us&edition=fundamental","pubTime":"2025-12-03 12:07","pubTimestamp":1764734864,"startTime":"0","endTime":"0","summary":"Amidst a backdrop of global economic uncertainty and shifting monetary policies, Asian markets have shown resilience, with investor interest particularly piqued by the potential for undervalued opportunities. In this context, identifying stocks priced below their intrinsic worth can be a strategic move for investors looking to capitalize on market inefficiencies and long-term growth potential.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/4021000-choice2-main-header/1585186704391","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4021000-choice2-main-header/1585186704391"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/cn/automobiles/shse-600166/beiqi-foton-motorltd-shares/news/asian-value-stocks-estimated-at-152-to-403-below-intrinsic-w","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/cn/automobiles/shse-600166/beiqi-foton-motorltd-shares/news/asian-value-stocks-estimated-at-152-to-403-below-intrinsic-w","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2399975544.HKD","LU2476274308.USD","LU0348766576.USD","LU0417516571.SGD","LU2476274720.SGD","IE00B5MMRT66.SGD","LU0348783233.USD","LU0348827113.USD","LU2488822045.USD","IE00B543WZ88.USD","LU1961090484.USD","LU2778985437.USD","LU0634319403.HKD","LU1794554557.SGD","LU0348784397.USD","LU0561508036.HKD","IE00BPRC5H50.USD","LU0348767384.USD","LU0348825331.USD","09926","LU0417516738.SGD","LU0417516902.SGD","LU0540923850.HKD","LU1720050803.USD","BK1161","LU0348735423.USD","BK1574"],"gpt_icon":0},{"id":"2588035860","title":"Asian Growth Stocks With High Insider Ownership December 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2588035860","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588035860?lang=en_us&edition=fundamental","pubTime":"2025-12-02 12:05","pubTimestamp":1764648351,"startTime":"0","endTime":"0","summary":"As Asian markets navigate a complex landscape marked by technological enthusiasm and economic uncertainties, investor interest in growth companies with high insider ownership has intensified. In this environment, stocks characterized by strong insider ownership can offer insights into management confidence and alignment of interests, making them compelling considerations for those looking to understand market dynamics.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/3051000-choice1-main-header/1585186568557","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3051000-choice1-main-header/1585186568557"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/cn/capital-goods/szse-300438/guangzhou-great-power-energy-and-technology-shares/news/asian-growth-stocks-with-high-insider-ownership-december-202","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/cn/capital-goods/szse-300438/guangzhou-great-power-energy-and-technology-shares/news/asian-growth-stocks-with-high-insider-ownership-december-202","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00B543WZ88.USD","LU0540923850.HKD","09926","LU2778985437.USD","LU2399975544.HKD","LU1961090484.USD","LU0417516902.SGD","LU2476274720.SGD","LU0417516571.SGD","LU2476274308.USD","LU0561508036.HKD","LU2488822045.USD","IE00BPRC5H50.USD","LU0634319403.HKD","IE00B5MMRT66.SGD","LU0348827113.USD","LU0348767384.USD","LU1794554557.SGD","LU0348784397.USD","LU0348766576.USD","BK1574","BK1161","LU1720050803.USD","LU0348783233.USD","LU0417516738.SGD","LU0348825331.USD","LU0348735423.USD"],"gpt_icon":0},{"id":"1157668357","title":"Southbound Capital Flow Data (T+2) for Dec 2","url":"https://stock-news.laohu8.com/highlight/detail?id=1157668357","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157668357?lang=en_us&edition=fundamental","pubTime":"2025-12-02 07:32","pubTimestamp":1764631967,"startTime":"0","endTime":"0","summary":"On November 27, Alibaba-W (09988), Pop Mart (09992), and China Merchants Bank (03968) topped the market in terms of net southbound capital inflows, recording inflows of HK$911 million, HK$442...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0588545730.USD","IE0032834883.USD","LU0543330566.HKD","LU2251237488.HKD","LU0516422440.USD","LU0203347892.USD","LU2008162690.USD","81810","LU0348783233.USD","BK1550","LU0737861772.HKD","LU1366334651.USD","LU0244354667.USD","LU1718418525.SGD","LU1655091616.SGD","LU0516423091.SGD","IE0032431581.USD","LU0049112450.USD","LU1235295612.USD","BK1095","LU1719994722.HKD","LU1629966141.USD","IE0003851619.USD","BK1137","LU2237443465.HKD","LU0488056044.USD","SG9999001226.SGD","LU1048588211.SGD","BK1242","06198","BK1241","LU0509642566.USD","HK0000306701.USD","LU2257852520.SGD","LU0633140727.USD","00777","LU0819121731.USD","LU1733274473.HKD","LU2543165471.USD","SG9999000459.SGD","LU0823039010.USD","IE00B0169N27.USD","BK1502","LU1515016050.SGD","LU0738912210.USD","LU1119993845.HKD","LU0823038988.USD","LU1794554557.SGD","LU1951186391.HKD","LU1808992512.USD","BK1240","BK1507","SG9999002562.SGD","BK1589","LU0228367735.SGD","BK1531","LU0856984785.SGD","SG9999001069.SGD","BK1501","LU1804176565.USD","02888","LU2097828474.EUR","03690","LU1115378108.SGD","LU0611395673.USD","LU0140636845.USD","SGXZ90724238.SGD","LU1831875114.USD","HBBD.SI","LU0269904917.USD","SGXZ99366536.SGD","SG9999002950.SGD","LU0251144936.SGD","LU0329678170.USD","LU1282651048.USD","BK1152","LU1770036033.HKD","LU0828237940.HKD","SG9999007991.SGD","BK1609","METmain","LU0708995153.HKD","03347","LU1634259391.SGD","BK1555","SG9999015952.SGD","LU0441854154.USD","00548","BK1184","LU1064131003.USD","LU1814569148.SGD","LU0865486749.SGD","BK1584","LU2488822045.USD","SG9999004220.SGD","IE00B8L5B284.USD","LU1064130708.USD","LU0231483743.USD","LU0577902454.USD","HTCD.SI","LU2237443978.SGD","LU0054450605.USD","02057","BK1161","BK1572","BK1583","LU0320764243.SGD","03323","BK1560","LU0143863198.USD","LU0315178854.USD","00081","BK1104","LU0345769631.USD","BK1133","LU0210533765.USD","BK1500","LU0499858602.USD","09926","LU2237443622.USD","LU0449515922.USD","LU2449936058.SGD","IE0003795394.USD","SG9999014906.USD","LU0463099449.HKD","SG9999017495.SGD","LU2097828557.USD","LU1105468828.SGD","LU0210527791.USD","LU0502904849.HKD","LU0326950275.SGD","03441","LU0039217434.USD","BK1227","SG9999013353.USD","00173","BK1575","LU0084288322.USD","SG9999001093.SGD","LU0096374516.USD","LU2237443382.USD","LU0516423174.USD","LU0414403682.SGD","LU0254981946.USD","LU1917777945.USD","LU0049853897.USD","IE0034224299.USD","LU0877626530.USD","LU0831093199.SGD","LU2293587155.HKD","LU0127658192.USD","LU0918141705.HKD","LU0128522157.USD","LU0229945570.USD","IE0009570106.USD","LU0543330483.HKD","LU1868837722.USD","LU0828238088.HKD","02169","LU2097828805.USD","LU0072462343.USD","LU1522347837.USD","SG9999001051.SGD","LU0348816934.USD","LU1048484197.HKD","SG9999012710.SGD","LU0577902611.USD","SG9999006514.SGD","LU3063872942.SGD","LU1960683339.HKD","02628","LU1981816686.USD","LU0651947912.USD","BK1610","BK1503","LU0149534421.HKD","LU0823413587.USD","LU1048596156.SGD","BK1518","LU1303224171.USD","LU0791590937.USD","IE00BPRC5H50.USD","LU1497734951.SGD","LU0348723411.USD","LU2048586759.USD","LU0823397103.USD","81024","LU0359201612.USD","LU0196878994.USD","00700","BK1521","LU0630378429.USD","BK1173","BK1526","01860","LU0266512127.USD","LU0605514214.HKD","HXXD.SI","LU0878004406.USD","LU0205439572.USD","LU2247934214.USD","LU0762541174.USD","BK1563","LU0149721374.USD","LU0228659784.USD","LU0499858438.USD","LU1226288097.SGD","LU1993786604.SGD","BK1541","LU0348788117.USD","LU2226246903.HKD","LU0683595622.HKD","IE00B067MR52.USD","LU0214875030.USD","09988","IE0031814852.USD","LU1720051017.SGD","LU2097829019.USD","LU1282648689.USD","LU1201861165.SGD","BK1506","LU0348825331.USD","LU0501845795.SGD","LU0650527681.SGD","LU2237443549.SGD","00107","BK1601","LU1242518857.USD","LU0784639295.USD","LU0348827113.USD","LU1226287875.USD","LU0348735423.USD","LU0173614495.USD","SG9999002463.SGD","LU2097828631.EUR","SG9999012736.USD","BK1231","00598","BK1576","LU0702159699.USD","LU1813983027.USD","LU2237443895.HKD","LU0455707207.USD","LU1720050803.USD","SG9999002828.SGD","LU0080751232.USD","LU1956131251.USD","IE00B031J352.USD","IE00B031HY20.USD","LU0188438112.USD","LU0700851271.USD","SG9999015945.SGD","LU2476274720.SGD","LU0314109678.HKD","02899","LU1785774172.SGD","LU0348766576.USD","LU0132412106.USD","SG9999001689.USD","SG9999014674.SGD","01024","BK1224","LU0821914370.USD","LU0130518102.USD","SG9999012728.SGD","BK1163","LU1769817096.USD","IE00B8HQ1Z84.USD","LU0831103253.SGD","LU1316542783.SGD","LU0572940350.SGD","LU2125910500.SGD","HK0000320264.USD","BK1183","BK1574","LU0918141887.USD","LU1102505762.USD","LU0345775950.USD","LU0067412154.USD","BK1214","HK0000252152.HKD","LU1044874839.SGD","LU0541502299.USD","LU1504937902.USD","LU1720051108.HKD","SG9999006597.SGD","LU0320764599.SGD","BK1616","BK1517","LU0540923850.HKD","HK0000306685.HKD","LU1328615791.USD","LU1196710351.USD","IE00B29SXG58.USD","IE00B031HW06.USD","LU0061477393.USD","BK1148","LU0823397285.USD","LU0572944931.SGD","LU0192582467.USD","LU0370786039.SGD","BK1615","LU1880383366.USD","LU2148510915.USD","80883","LU0456842615.SGD","BK1536","LU0348805143.USD","LU1655091459.SGD","LU0594300419.USD","BK1236","LU0823426308.USD","LU0577902538.SGD","LU0329678337.USD","LU0477156797.USD","LU1152091754.HKD","LU0175139822.USD","LU0873338254.USD","LU1251922891.USD","LU2106854487.HKD","IE00BZ08YT58.USD","LU0828237510.HKD","LU0640798160.USD","LU0588545490.SGD","LU1196710195.USD","LU1226288170.HKD","LU0633140560.USD","LU1883866441.USD","LU0048388663.USD","SG9999014880.SGD","BK1516","LU0264606111.USD","00762","LU0871576103.HKD","IE00BZ08YS42.EUR","LU0791591158.USD","SG9999003461.SGD","LU2051468812.USD","BK1580","LU2125910849.SGD","BK1618","IE00B3M56506.USD","LU2045819591.USD","LU0029874905.USD","LU1568876335.HKD","SG9999014914.USD","LU0128522744.USD","LU0164872284.USD","LU0348767384.USD","SGXZ31699556.SGD","LU0164865239.USD","IE00BQXX3D17.EUR","LU0348784397.USD","LU1880398471.USD","LU1497733557.USD","IE00BYV24P56.USD","00981","LU1023057109.AUD","06969","LU0293314216.USD","LU0261947096.USD","LU0107464264.USD","BK1151","BK1586","LU0823041008.USD","LU0531971595.HKD","LU1734074674.USD","LU2362540622.SGD","LU1211504680.USD","IE00BGHQDM52.EUR","LU0106259558.USD","LU1733274390.USD","LU0577902371.SGD","LU0630378692.HKD","LU2476274308.USD","LU1166156734.SGD","IE00B97KM107.HKD","BK1142","LU0608807946.USD","LU0181495838.USD","SG9999015986.USD","09880","LU0384037296.USD","BK1512","LU1439103000.SGD","LU1770034418.SGD","LU1008478684.HKD","XIACY","00941","LU1880398554.USD","IE00BQXX3F31.USD","LU2362541513.USD","SG9999000418.SGD","LU0164880469.USD","LU0345780521.USD","LU1152091168.USD","01361","LU0868486357.SGD","LU1282649067.USD","LU0898667661.SGD","LU2023250504.SGD","02255","SG9999001903.USD","BK1519","LU1439102457.SGD","BK1588","LU0979878070.USD","LU1868837565.USD","BK1567","LU0708995583.HKD","LU0070217475.USD","LU2399975544.HKD","HK0000165453.HKD","SGXZ62798434.SGD","LU0048597586.USD","LU0417516902.SGD","KSTmain","LU0819123356.HKD","IE00BGV7N243.SGD","LU0197773673.USD","LU0345776255.USD","BK1582","LU1282651121.HKD","LU1868838027.USD","BK1535","LU0593848301.USD","BK1505","LU0577902298.EUR","02555","LU0594300179.USD","BK1591","HMTD.SI","LU0266512473.USD","LU0469268626.HKD","IE00BMPRXR70.SGD","LU0289960550.SGD","LU0516422366.SGD","LU2177674079.SGD","LU1642822792.SGD","BK1594","LU0011963245.USD","LU0648000940.SGD","LU2317271919.USD","STAN.UK","LU0516422952.EUR","06690","BK1544","LU0823413660.USD","BK1186","LU0823426480.USD","LU0348783662.USD","LU0143863784.USD","LU0345769128.USD","LU2087589342.USD","03877","LU0106959298.USD","LU0880133367.SGD","LU0878005551.USD","LU1044876610.USD","LU0235996351.USD","LU1196710864.SGD","LU1242518931.SGD","BK1135","LU0315179316.USD","IE00BMCWC346.EUR","LU0396098781.USD","BK1592","LU0541501648.USD","BK1590","LU1046422090.SGD","LU1328277881.USD","LU1634259557.SGD","BK1614","LU0417516738.SGD","IE0008368742.USD","SG9999018857.SGD","BK1141","LU1224444064.USD","IE00BZ08YR35.GBP","LU2362541273.HKD","LU0203345920.USD","LU0359202008.SGD","SG9999012744.USD","LU1224709979.USD","LU1974910355.USD","LU0054237671.USD","LU0211977185.USD","LU1568876251.USD","IE00B5MMRT66.SGD","LU0431992006.USD","LU1323998911.USD","SGXZ86797644.SGD","LU1226287792.SGD","BK1249","LU0972618739.USD","LU0072913022.USD","LU0823040885.USD","IE00BF5LJ272.USD","LU0211331839.USD","BK1193","BK1604","89988","SG9999000327.SGD","LU1807302812.USD","LU0051755006.USD","LU0326948709.USD","GB00BDT5M118.USD","HK0000252160.HKD","LU0320764755.SGD","LU0165289439.USD","LU2265009873.SGD","IE00BQXX3C00.GBP","LU0052750758.USD","LU0890818403.SGD","LU1675838814.USD","LU2242644610.SGD","LU2498475776.HKD","LU0029875118.USD","LU0634319403.HKD","IE0003895053.USD","LU1051768304.USD","LU1688375341.USD","LU0163747925.USD","LU1044875133.USD","LU0762540952.USD","LU0417516571.SGD","09606","LU0985320562.USD","LU2251237306.USD","IE00BMPRXN33.USD","LU1481107354.HKD","LU2357305700.SGD","LU0169518387.USD","LU1102505929.USD","LU0589944569.HKD","LU1188198961.HKD","LU1810669033.SGD","LU0456846285.SGD","IE0008368411.USD","LU0862451837.USD","03968","LU0702159343.USD","LU0762542818.HKD","LU0261950983.USD","LU0648948544.HKD","LU0117841782.USD","BK1557","LU0737861699.HKD","IE0001KFT4U8.USD","03143","BK1607","06818","LU0210526637.USD","LU0607220059.USD","IE0008368304.USD","LU0449509016.USD","LU0259732245.USD","LU0130103400.USD","LU2778985437.USD","LU0786609619.USD","LU0327786744.USD","LU0048580855.USD","LU0572939691.SGD","HK0000320223.HKD","LU1548497426.USD","LU0456854461.SGD","LU2133065610.SGD","BK1233","BK1565","LU0675040207.SGD","LU0106252389.USD","LU0043850808.USD","LU1961090484.USD","BK1185","IE00B0JY6N72.USD","LU1226288253.USD","LU1497733631.SGD","LU1769817179.HKD","LU2039709279.SGD","LU1725190679.HKD","01810","LU0882747503.HKD","LU1282649810.SGD","BK1608","LU0117844026.USD","IE00B543WZ88.USD","LU0651946864.USD","BK1523","LU2097828714.EUR","03033","IE00B0169L03.USD","LU0345780281.USD","LU0862451753.SGD","LU0197773160.USD","LU0886674414.USD","LU0328353924.USD","LU2152927971.USD","BK1198","LU0588545904.SGD","IE0008369823.USD","LU0287142896.SGD","SG9999018865.SGD","SG9999014898.SGD","IE00BVYPNP33.GBP","LU2279701549.SGD","BK1619","LU1226287529.USD","01186","LU0608807433.USD","LU1051769294.HKD","LU0047713382.USD","LU1366334578.USD","IE00BVYPNQ40.USD","LU0642271901.SGD","SG9999015978.USD","LU0531970944.HKD","09992","BK1613","HK0000500386.USD","LU0797268264.HKD","LU0672654166.SGD","LU2462611646.USD","LU0307460666.USD","LU0456827905.SGD","MPNGY","SGXZ51526630.SGD","LU0359201885.HKD","SGXZ81514606.USD","LU1282649141.HKD","LU0348814723.USD","LU0561508036.HKD","LU1880383440.USD","LU0588546209.SGD","SG9999001846.SGD"],"gpt_icon":1},{"id":"2586420978","title":"Does Akeso’s (SEHK:9926) First Alzheimer’s Bispecific Antibody Approval Reinvent Its Innovation Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2586420978","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586420978?lang=en_us&edition=fundamental","pubTime":"2025-11-25 16:15","pubTimestamp":1764058503,"startTime":"0","endTime":"0","summary":"Earlier this month, Akeso, Inc. announced that its novel bispecific antibody AK152 received approval from the National Medical Products Administration (NMPA) to begin clinical trials for Alzheimer's Disease, marking the first such therapy of its kind developed in China for disease modification. \nThis milestone also signifies Akeso's entry into innovative central nervous system therapeutics, leveraging enhanced brain penetration and robust preclinical results for potential next-generation...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/does-akesos-sehk9926-first-alzheimers-bispecific-antibody-ap","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/does-akesos-sehk9926-first-alzheimers-bispecific-antibody-ap","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1961090484.USD","LU2778985437.USD","LU1720050803.USD","LU0348825331.USD","LU0348767384.USD","BK1574","LU0417516738.SGD","LU0348784397.USD","LU2488822045.USD","LU0348735423.USD","BK1161","IE00BPRC5H50.USD","IE00B543WZ88.USD","09926","LU0348827113.USD","LU0417516571.SGD","LU0634319403.HKD","LU0348766576.USD","LU2399975544.HKD","LU2476274308.USD","LU0417516902.SGD","LU0540923850.HKD","LU1794554557.SGD","LU0348783233.USD","LU2476274720.SGD","IE00B5MMRT66.SGD","LU0561508036.HKD"],"gpt_icon":0},{"id":"2585197407","title":"Akeso (SEHK:9926) Valuation: Assessing Pipeline Momentum After Landmark Alzheimer’s and Oncology R&D Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2585197407","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585197407?lang=en_us&edition=fundamental","pubTime":"2025-11-21 11:26","pubTimestamp":1763695588,"startTime":"0","endTime":"0","summary":"Akeso (SEHK:9926) has just been cleared by China’s National Medical Products Administration to initiate clinical trials for AK152, its first bispecific antibody aimed at tackling Alzheimer’s Disease, and a breakthrough in the domestic biotech space.\nSee our latest analysis for Akeso.\nWhile Akeso's progress on Alzheimer's and its oncology advances have kept it in the headlines, the share price has pulled back 36% over the past three months after a rapid rally earlier this year. Still, the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-valuation-assessing-pipeline-momentum-after-l","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-valuation-assessing-pipeline-momentum-after-l","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00BPRC5H50.USD","09926","LU1057294990.SGD","IE0002270589.USD","LU0289739699.SGD","LU0306807586.USD","IE00B543WZ88.USD","LU2399975544.HKD","LU0634319403.HKD","LU1720050803.USD","BK4533","BK4534","IE000M9KFDE8.USD","LU0348827113.USD","LU1883839398.USD","LU0321505868.SGD","LU1894683348.USD","BK4585","IE00B19Z3581.USD","SG9999013999.USD","BK4588","BK1574","LU1961090484.USD","SG9999001176.SGD","SGXZ57979304.SGD","LARK","LU0348767384.USD","LU0348735423.USD","LU0348825331.USD","LU2488822045.USD","LU0348766576.USD","LU0561508036.HKD","LU1023059063.AUD","SG9999002224.SGD","BK4211","BK4550","LU1066051498.USD","SG9999011175.SGD","LU2778985437.USD","BK1161","IE00BBT3K403.USD","LU0868494617.USD","LU0321505439.SGD","IE00B19Z3B42.SGD","LU2476274720.SGD","LU0540923850.HKD","LU0417516571.SGD","IE00B5MMRT66.SGD","LU0348783233.USD"],"gpt_icon":1},{"id":"2584349618","title":"Akeso Wins China Approval to Begin Clinical Trials of Bispecific Antibody for Alzheimer's","url":"https://stock-news.laohu8.com/highlight/detail?id=2584349618","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584349618?lang=en_us&edition=fundamental","pubTime":"2025-11-17 10:29","pubTimestamp":1763346595,"startTime":"0","endTime":"0","summary":"Akeso Inc. has received regulatory approval from China's National Medical Products Administration  to initiate clinical trials for AK152, a novel bispecific antibody targeting both amyloid-beta (Aβ) and a blood-brain barrier  expressed receptor for the treatment of Alzheimer's Disease. AK152 is the first bispecific antibody developed in China for this indication, marking a significant advancement in disease-modifying therapy for Alzheimer's. The approval allows Akeso to begin clinical studies, following promising preclinical results demonstrating robust bioactivity, improved brain penetration, and accelerated clearance of Aβ plaques. No other organizations were mentioned as recipients of this approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDLbhZXxt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348825331.USD","LU0634319403.HKD","LU1720050803.USD","LU0348827113.USD","LU2476274308.USD","LU0540923850.HKD","09926","BK1161","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU0348784397.USD","LU1961090484.USD","LU0417516738.SGD","LU0348783233.USD","LU2399975544.HKD","LU0561508036.HKD","LU0417516902.SGD","LU0417516571.SGD","LU0348735423.USD","LU0348766576.USD","LU2778985437.USD","LU0348767384.USD","LU1794554557.SGD","LU2476274720.SGD","LU2488822045.USD","BK1574"],"gpt_icon":0},{"id":"2584618896","title":"Akeso's Bispecific Antibody Targeting aΒ and Bbb-Expressed Receptor Approved for Alzheimer's Disease Clinical Trials in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2584618896","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584618896?lang=en_us&edition=fundamental","pubTime":"2025-11-17 10:29","pubTimestamp":1763346581,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nTUA7TKWPS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","LU2399975544.HKD","LU2476274720.SGD","09926","LU0417516902.SGD","LU0634319403.HKD","LU2488822045.USD","LU0348735423.USD","IE00B5MMRT66.SGD","LU0348825331.USD","LU1794554557.SGD","LU1961090484.USD","LU2476274308.USD","LU0417516738.SGD","LU1720050803.USD","IE00BPRC5H50.USD","IE00B543WZ88.USD","LU0417516571.SGD","LU0561508036.HKD","LU2778985437.USD","BK1574","LU0348767384.USD","LU0540923850.HKD","LU0348766576.USD","LU0348784397.USD","LU0348783233.USD","LU0348827113.USD"],"gpt_icon":0},{"id":"1116544257","title":"Market Outlook: Heavy Pressure This Week; Focus on NVIDIA (NVDA.US) Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=1116544257","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116544257?lang=en_us&edition=fundamental","pubTime":"2025-11-17 09:12","pubTimestamp":1763341959,"startTime":"0","endTime":"0","summary":"Last week, the U.S. government shutdown came to an end, briefly boosting sentiment in Hong Kong stocks. However, new concerns emerged, and the Hang Seng Index weakened again on Friday. Over the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"5a4dd5d101c804e53ef17d3dc5fe87e6","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1069344957.HKD","SG9999018857.SGD","LU2381873111.SGD","LU0345768740.USD","BK4587","LU0345768153.USD","LU0072462426.USD","LU0323591593.USD","LU0061474960.USD","LU2092937148.SGD","IE0004445239.USD","BK4527","LU0823434583.USD","LU1914381329.SGD","LU2265009873.SGD","LU2125909593.SGD","BK4532","LU1145028129.USD","LU2756315664.SGD","IE00BJLML261.HKD","LU1699723380.USD","LU1917777945.USD","LU2168563687.JPY","LU0203202063.USD","LU0308772762.SGD","LU1720051108.HKD","IE00BWXC8680.SGD","LU2750360641.GBP","LU0096362180.USD","LU0348723411.USD","LU2473716301.USD","LU0274383776.USD","2NVD.UK","IE00BMPRXQ63.HKD","LU0823421416.USD","LU1791710400.SGD","LU0689472784.USD","LU1983260115.SGD","SGXZ51526630.SGD","IE00BQXX3F31.USD","LU1935043536.SGD","LU2461242641.AUD","IE00BZ1G4Q59.USD","BK1161","LU0820562030.AUD","LU2191332357.HKD","LU2413666699.HKD","LU0528227936.USD","HK0000320264.USD","LU0359201612.USD","LU2430703251.USD","LU1861220033.SGD","LU0070217475.USD","LU0683600562.USD","IE0034235295.USD","LU0494093205.USD","LU1814569148.SGD","LU1119994496.HKD","IE00BD6J9T35.USD","LU0029864427.USD","LU0048584097.USD","LU1548497426.USD","LU0128525929.USD","LU1244550577.SGD","LU1674673428.USD","LU0348827113.USD","LU0211327993.USD","LU2023250504.SGD","01276","SG9999015358.SGD","LU0345770308.USD","LU0056508442.USD","LU2108987350.USD","LU0266013472.USD","LU0238689110.USD","LU2087621335.USD","BK4548","LU2399975544.HKD","LU2420271590.USD","LU2290526834.HKD","BK4608","LU0348784397.USD","LU0502904849.HKD","LU0882574139.USD","LU0353189763.USD","NVD2.UK","IE0034235188.USD","LU2168564495.EUR","LU2361045086.USD","IE00BMPRXR70.SGD","LU0359202008.SGD","SG9999014880.SGD","IE00BHPRN162.USD","LU0345769631.USD","LU1720051017.SGD","LU1280957306.USD","LU2097828557.USD","LU0069063385.USD","LU1868837136.USD","LU1261432733.SGD","LU1868836757.USD","LU0310800379.SGD","LU0964807845.USD","SG9999015945.SGD","LU2471134523.USD","LU0061475181.USD","LU0942090050.USD","LU2125909759.SGD","LU2264538146.SGD","LU2360106780.USD","IE0004086264.USD","LU1923622614.USD","LU2931357623.SGD","LU0444973449.USD","NVDD","BK1589","IE00B19Z8W00.USD","LU2552382215.SGD","GB00BDT5M118.USD","LU0094547139.USD","IE00B5MMRT66.SGD","LU1066051498.USD","LU0097036916.USD","BK4543","LU0390134368.USD","LU0265550359.USD","LU0154236417.USD","LU0225283273.USD","LU2249611893.SGD","IE00BK4W5M84.HKD","LU1551013342.USD","LU0359201885.HKD","LU2458330243.SGD","LU2237957811.SGD","LU0082616367.USD","LU1116320737.USD","LU2294711713.HKD","LU2896262040.SGD","LU2065170008.USD","IE00BKDWB100.SGD","IE0001KFT4U8.USD","LU0889565833.HKD","LU1989764664.SGD","LU2505996681.GBP","LU1244550221.USD","LU0417517546.SGD","LU2237438978.USD","LU0316494557.USD","LU2456880835.USD","LU0251132253.USD","LU0109391861.USD","LU0965509101.SGD","LU0198837287.USD","LU0957791311.USD","LU2403377893.USD","BK4551","LU2097344431.USD","LU1267930573.SGD","LU1721428933.USD","LU1778281490.HKD","LU0267386448.USD","IE00B775H168.HKD","LU0417516738.SGD","IE00BDCRKT87.USD","LU1064131342.USD","LU1242518857.USD","LU2065169927.USD","LU2097828714.EUR","LU1974910355.USD","IE00BFSS8Q28.SGD","LU2417539215.USD","SG9999002232.USD","IE00BJTD4N35.SGD","LU2242649171.HKD","SG9999002224.SGD","LU0053666078.USD","LU0965508806.USD","LU1316542783.SGD","HK0000306701.USD","LU1718418525.SGD","LU0724617625.USD","LU0289960550.SGD","LU1992135399.USD","LU2168564065.EUR","LU0158827948.USD","09926","LU0557290698.USD","SG9999015978.USD","LU1961090484.USD","LU1989772923.USD","LU0342679015.USD","BK4567","LU0345770993.USD","LU1935042488.USD","LU2360032135.SGD","NVDL","NVDU","LU0210528500.USD","01801","SGXZ23171101.USD","BK4549","LU0689626769.HKD","NVDS","LU2488822045.USD","LU1951200564.SGD","LU2092627202.USD","LU0158827781.USD","LU0719512351.SGD","LU1861215975.USD","LU0786609619.USD","LU2271345857.HKD","LU0868494708.USD","LU2125154935.USD","LU2272731865.HKD","LU2063271972.USD","BK1583","LU1934455863.HKD","BK1574","LU0511384066.AUD","LU1429558221.USD","LU0348767384.USD","LU1116320901.HKD","LU0234570918.USD","SG9999014559.SGD","LU2028103732.USD","LU0540923850.HKD","HK0000306685.HKD","SG9999004303.SGD","LU0347712357.USD","LU0965509283.SGD","BK4588","LU0187121727.USD","LU2168564149.EUR","BK4141","LU2360107168.USD","LU0265550946.USD","LU1821325948.USD","LU0455707207.USD","IE00B4JS1V06.HKD","BK4579","NVDX","IE00B1BXHZ80.USD","LU1642822529.SGD","LU2357305700.SGD","LU2328871848.SGD","IE00BN29S564.USD","LU0354030438.USD","LU2602419157.SGD","LU1803068979.SGD","SG9999000418.SGD","BK4592","LU2244417387.USD","LU0210536198.USD","LU2326559502.SGD","LU2452424414.USD","LU1066053197.SGD","LU1951198990.SGD","LU2054465674.USD","LU0861579265.USD","LU0210533765.USD","LU0348783233.USD","IE0005OL40V9.USD","LU2458330169.SGD","BK4605","LU0820561818.USD","LU0096364046.USD","LU1969619763.USD","NVIW.SI","LU1084165304.USD","LU2505996509.AUD","LU2272731600.USD","LU1935043023.USD","LU0417516571.SGD","LU1066051811.HKD","LU2250418816.HKD","LU0170899867.USD","LU1323610961.USD","LU0634319403.HKD","NVD3.UK","LU2471134952.CNY","HK0000165453.HKD","LU0823414551.USD","LU1712237335.SGD","BK4550","LU0348735423.USD","LU1868836914.USD","IE00BFSS7M15.SGD","LU1923622291.USD","LU2111349929.HKD","IE00B5949003.HKD","IE00BDRTCR15.USD","SG9999018865.SGD","LU2491050154.USD","LU1571399168.USD","LU2168564222.USD","BK4503","SGXZ99366536.SGD","LU2361044865.SGD","LU0417516902.SGD","IE0004091025.USD","LU1551013425.SGD","LU1839511570.USD","LU1935042215.USD","LU0957808578.USD","LU2361044949.HKD","LU1037948897.HKD","LU0708994859.HKD","LU0823434740.USD","LU2430703095.HKD","LU2211815571.USD","IE00BQXX3C00.GBP","BK4612","LU1815336760.USD","LU0157215616.USD","LU2322448957.HKD","LU2065171402.SGD","LU1988902786.USD","SG9999017495.SGD","LU0215105999.USD","LU2463028550.USD","LU0642271901.SGD","LU0348766576.USD","LU0708995401.HKD","LU1066051225.USD","LU0256863811.USD","LU2242650005.HKD","LU2236285917.USD","LU0965509010.AUD","HK0000320223.HKD","IE00BK4W5L77.USD","LU1868836591.USD","NVDA","LU2552382058.USD","IE00BPRC5H50.USD","SG9999014567.USD","IE00BJJMRX11.SGD","LU0289961442.SGD","IE00B3M56506.USD","LU1267930490.SGD","LU0640476718.USD","LU0234572021.USD","LU0943347566.SGD","LU2756315318.SGD","LU2462157665.USD","LU0006306889.USD","LU1720050803.USD","LU2065171311.SGD","LU2357125470.USD","IE00BJJMRY28.SGD","LU0077335932.USD","LU1366192091.USD","LU0472753341.HKD","IE0009356076.USD","SG9999014575.USD","LU0211328371.USD","LU2023250330.USD","LU1934455277.USD","LU1852331112.SGD","LU1791710582.SGD","LU2106854487.HKD","LU0672654240.SGD","LU0354030511.USD","NVD","LU2750360997.AUD","LU0256863902.USD","LU0203201768.USD","LU1035775433.USD","LU1127390331.HKD","LU1992135472.HKD","LU1989772840.SGD","SG9999014906.USD","LU1023057109.AUD","BK4585","LU1496350502.SGD","LU1815333072.USD","SG9999014914.USD","LU2746668461.USD","LU0823421333.USD","LU2237957902.USD","BK4533","LU1674673691.USD","IE00B1XK9C88.USD","IE00BKPKM429.USD","LU2778985437.USD","LU1244550494.USD","LU0444971666.USD","LU0345769128.USD","LU1989764748.USD","LU2213496289.HKD","06990","IE00BMPRXN33.USD","LU2746668974.SGD","LU1804176565.USD","LU0196878994.USD","LU2097828631.EUR","LU0107464264.USD","3NVD.UK","SG9999014542.SGD","LU0320765059.SGD","LU1242518931.SGD","BK1191","LU0081259029.USD","LU0124676726.USD","LU2552382132.HKD","LU2089985449.USD","IE00BJTD4V19.USD","LU2471134796.USD","LU2242644610.SGD","LU0820561909.HKD","LU0289739343.SGD","LU0561508036.HKD","LU2089283258.USD","SNVD.UK","SGXZ81514606.USD","NVDS.UK","LU0109392836.USD","LU2430703178.SGD","LU0348825331.USD","LU1861127337.USD","LU2077746001.SGD","SG9999015986.USD","LU2322448791.USD","BK4554","LU2097828474.EUR","LU0276348264.USD","IE00BYXW3230.USD","LU2476274720.SGD","LU1794554557.SGD","LU2491049909.HKD","IE00BZ199S13.USD","LU2247934214.USD","LU0868494617.USD","LU2083900584.USD","LU2491050071.SGD","LU2543165471.USD","LU2125909247.SGD","LU1037948541.HKD","LU2125154778.USD","SG9999014898.SGD","IE00B19Z8X17.USD","LU0985320562.USD","LU2125909916.SGD","LU2286300806.USD","LU0079474960.USD","LU2272731782.SGD","LU2506951792.HKD","LU0788109477.HKD","LU0476273544.USD","BK4614","SG9999001424.SGD","SG9999015341.SGD","LU0310799852.SGD","IE0004445015.USD","LU1935042991.SGD","LU1633808545.USD","LU1923623000.USD","LU0175139822.USD","LU1868837300.USD","IE00BKVL7J92.USD","LU1232071149.USD","LU2860962120.EUR","IE00B19Z9505.USD","BK4534","LU2433249047.HKD","LU1435385759.SGD","LU2087625088.SGD","LU0979878070.USD","LU1623119135.USD","LU2487616109.SGD","LU0127658192.USD","LU0057025933.USD","LU1496350171.SGD","LU2097828805.USD","LU0823414478.USD","IE00B7KXQ091.USD","BK4529","LU0106261372.USD","IE00B543WZ88.USD","SG9999015952.SGD","LU0061474705.USD","BK4598","LU0466842654.USD","LU2089284900.SGD","LU2476274308.USD","LU1934455194.USD","LU2471134879.HKD","LU0787776722.HKD","BK4581","LU1366333091.USD","LU1629891620.HKD","NVDY","LU1267930730.SGD","LU2413666426.HKD","LU2097344357.USD","LU2592432038.USD","SGXZ31699556.SGD","IE00BQXX3D17.EUR","LU0080751232.USD","LU0353189680.USD","IE0034235303.USD","LU2023251221.USD"],"gpt_icon":1},{"id":"1151848502","title":"CITIC Securities: Rates AKESO (09926) as \"Buy\" on Strong Efficacy and Broad Market Potential of Innovative Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=1151848502","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151848502?lang=en_us&edition=fundamental","pubTime":"2025-11-13 16:50","pubTimestamp":1763023857,"startTime":"0","endTime":"0","summary":"CITIC Securities released a research report highlighting AKESO's (09926) robust R&D pipeline, with multiple investigational products and indications nearing approval. The company continues to expand...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348825331.USD","LU0417516738.SGD","IE00B543WZ88.USD","LU0540923850.HKD","LU2778985437.USD","LU2399975544.HKD","LU0348767384.USD","LU2488822045.USD","06978","IE00BPRC5H50.USD","159992","LU0348766576.USD","LU0348784397.USD","LU0417516571.SGD","IE00B5MMRT66.SGD","BK1161","LU2476274308.USD","LU2476274720.SGD","09926","BK1574","LU1961090484.USD","LU0348735423.USD","LU1794554557.SGD","LU0348827113.USD","LU0348783233.USD","LU0561508036.HKD","LU0634319403.HKD","LU0417516902.SGD","LU1720050803.USD"],"gpt_icon":0},{"id":"2583373505","title":"The Bull Case For Akeso (SEHK:9926) Could Change Following New Oncology Pipeline Milestones and Clinical Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583373505","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583373505?lang=en_us&edition=fundamental","pubTime":"2025-11-13 12:49","pubTimestamp":1763009381,"startTime":"0","endTime":"0","summary":"In early November 2025, Akeso announced a series of pipeline milestones, including the first patient dosing in a Phase I trial of its mRNA vaccine AK154, the presentation of promising Overall Survival results for ivonescimab in EGFR-mutated non-small cell lung cancer at SITC, and new preclinical data for its novel antibody AK135.\nThe rapid progress across both late-stage and innovative early-stage assets underscores Akeso's efforts to expand its oncology portfolio while solidifying its...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/the-bull-case-for-akeso-sehk9926-could-change-following-new","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/the-bull-case-for-akeso-sehk9926-could-change-following-new","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0348735423.USD","LU2476274720.SGD","LU1961090484.USD","LU0348766576.USD","LU0540923850.HKD","LU2778985437.USD","LU0634319403.HKD","LU0417516902.SGD","LU0348784397.USD","LU0561508036.HKD","LU2399975544.HKD","LU1794554557.SGD","IE00B543WZ88.USD","LU0348825331.USD","BK1574","LU0348783233.USD","LU0417516738.SGD","09926","LU0417516571.SGD","LU2488822045.USD","LU1720050803.USD","LU2476274308.USD","LU0348827113.USD","IE00B5MMRT66.SGD","BK1161","LU0348767384.USD","IE00BPRC5H50.USD"],"gpt_icon":0},{"id":"1112478778","title":"HK Movers | Innovative Drug Stocks Jump With Ascletis Pharma and BeOne Medicines up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1112478778","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112478778?lang=en_us&edition=fundamental","pubTime":"2025-11-12 10:00","pubTimestamp":1762912816,"startTime":"0","endTime":"0","summary":"Innovative drug stocks jumped in Hong Kong. Ascletis Pharma and BeOne Medicines rose 6%; Akeso rose 4%; Jinxin Fertility rose 2%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"93ca2ea8f560905425dc4dda4a045e37","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01951","01672","09926","06160"],"gpt_icon":0},{"id":"1172850038","title":"HK Stock Movement | AKESO (09926) Rises Nearly 5% as Phase I Clinical Trial of AK154 Monotherapy or Combined with Cadonilimab/Ivonescimab Completes First Dosing for Pancreatic Cancer Adjuvant Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1172850038","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172850038?lang=en_us&edition=fundamental","pubTime":"2025-11-12 10:00","pubTimestamp":1762912815,"startTime":"0","endTime":"0","summary":"AKESO (09926) surged nearly 5%, reaching HK$119.9 by the time of writing, with a trading volume of HK$310 million. The company announced via its official WeChat account that the first patient has...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348766576.USD","IE00BPRC5H50.USD","09926","BK1161","LU2488822045.USD","LU2778985437.USD","LU0417516571.SGD","LU0348735423.USD","LU1794554557.SGD","LU0417516902.SGD","BK1574","LU0348784397.USD","LU1961090484.USD","LU0348825331.USD","LU1720050803.USD","LU0417516738.SGD","LU0348767384.USD","LU0634319403.HKD","LU0540923850.HKD","LU2476274308.USD","LU0348827113.USD","LU0561508036.HKD","IE00B5MMRT66.SGD","LU2476274720.SGD","LU0348783233.USD","LU2399975544.HKD","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2582878522","title":"Akeso Begins Phase I Trial of Personalized mRNA Vaccine AK154 for Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2582878522","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582878522?lang=en_us&edition=fundamental","pubTime":"2025-11-10 19:40","pubTimestamp":1762774805,"startTime":"0","endTime":"0","summary":"Akeso Inc. has announced that the first patient has been dosed in a Phase I clinical trial of its personalized mRNA vaccine candidate AK154 for the adjuvant treatment of pancreatic cancer. The study will evaluate AK154 as a monotherapy and in combination with Akeso's bispecific antibodies, cadonilimab  and ivonescimab , following surgical resection. AK154 is Akeso's first mRNA-based therapeutic candidate to enter clinical development. According to the company, preclinical data showed strong immunogenicity, potent anti-tumor activity, and a favorable safety profile. Clinical results from this trial have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL7K36gv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1961090484.USD","LU0634319403.HKD","LU2488822045.USD","IE00BPRC5H50.USD","LU2778985437.USD","LU2476274720.SGD","LU0348827113.USD","IE00B5MMRT66.SGD","LU0348735423.USD","LU0540923850.HKD","BK1161","LU0348766576.USD","LU0417516902.SGD","LU2476274308.USD","LU1720050803.USD","LU0348767384.USD","LU0561508036.HKD","LU2399975544.HKD","LU1794554557.SGD","IE00B543WZ88.USD","LU0348825331.USD","LU0417516738.SGD","LU0417516571.SGD","LU0348783233.USD","LU0348784397.USD","BK1574","09926"],"gpt_icon":0},{"id":"2582878396","title":"Akeso Announces First Patient Dosed in Phase I Trial of Personalized Mrna Vaccine Ak154 as Monotherapy or in Combination With Cadonilimab or Ivonescimab for Adjuvant Treatment of Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2582878396","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582878396?lang=en_us&edition=fundamental","pubTime":"2025-11-10 19:39","pubTimestamp":1762774775,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nTUABFNNG3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0417516738.SGD","LU0348766576.USD","LU1794554557.SGD","LU2778985437.USD","LU0417516902.SGD","LU0348735423.USD","LU0540923850.HKD","IE00B5MMRT66.SGD","LU0348825331.USD","LU1961090484.USD","LU0634319403.HKD","LU2476274720.SGD","IE00BPRC5H50.USD","LU0348783233.USD","LU0561508036.HKD","LU1720050803.USD","BK1574","LU2476274308.USD","LU0417516571.SGD","LU0348767384.USD","LU2488822045.USD","LU2399975544.HKD","09926","BK1161","IE00B543WZ88.USD","LU0348784397.USD","LU0348827113.USD"],"gpt_icon":0},{"id":"2581188717","title":"Akeso Inc. Wins China Approval for Ivonescimab in EGFR-Mutated NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2581188717","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581188717?lang=en_us&edition=fundamental","pubTime":"2025-11-08 00:30","pubTimestamp":1762533030,"startTime":"0","endTime":"0","summary":"Akeso Inc. announced that ivonescimab, its novel therapy for EGFR-mutated non-squamous non-small cell lung cancer  following EGFR-TKI progression, received regulatory approval from the China National Medical Products Administration in May 2024. The drug was subsequently added to China's National Reimbursement Drug List  in November 2024, ensuring broad patient access starting January 1, 2025. Additionally, Akeso's global partner, Summit Therapeutics, plans to submit a Biologics License Application  to the U.S. FDA in the fourth quarter of 2025 for the same indication.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire  on November 07, 2025, and is so","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL4vjRW0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720050803.USD","LU0417516571.SGD","LU0348825331.USD","LU2488822045.USD","09926","LU0561508036.HKD","LU0348827113.USD","LU0348735423.USD","LU0348784397.USD","LU2399975544.HKD","BK4139","BK1574","LU0634319403.HKD","LU2476274308.USD","SMMT","LU0417516902.SGD","IE00B543WZ88.USD","LU2778985437.USD","LU1961090484.USD","BK1161","LU0540923850.HKD","LU0348783233.USD","IE00BPRC5H50.USD","LU2476274720.SGD","LU0348767384.USD","LU0417516738.SGD","LU1794554557.SGD","IE00B5MMRT66.SGD","LU0348766576.USD"],"gpt_icon":0},{"id":"2581887170","title":"Akeso Reports AK135 Antibody Blocks Key Inflammatory Pathways and Relieves Neuropathy Pain in Preclinical Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2581887170","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581887170?lang=en_us&edition=fundamental","pubTime":"2025-11-08 00:30","pubTimestamp":1762533023,"startTime":"0","endTime":"0","summary":"Akeso Inc. has announced promising preclinical research results for its novel monoclonal antibody, AK135, which targets the IL-1 receptor accessory protein . The results were presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer  in 2025. AK135 demonstrated high affinity for IL-1RAP and effectively blocked the IL-1, IL-33, and IL-36 pro-inflammatory signaling pathways in vitro, leading to reduced secretion of inflammatory cytokines. In animal models of chemotherapy-induced peripheral neuropathy, AK135 provided significant, dose-dependent pain relief without notable toxicity. These findings suggest AK135 could offer a new treatment option for neuropathic pain in cancer patients.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL7b1RHD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417516902.SGD","LU0348827113.USD","LU2488822045.USD","LU1961090484.USD","LU0417516738.SGD","LU2476274720.SGD","IE00B543WZ88.USD","LU0561508036.HKD","LU0348735423.USD","LU0634319403.HKD","BK1161","LU1720050803.USD","LU0348784397.USD","LU0348825331.USD","09926","LU0348766576.USD","LU2778985437.USD","IE00BPRC5H50.USD","LU0417516571.SGD","LU1794554557.SGD","LU2476274308.USD","IE00B5MMRT66.SGD","LU0348767384.USD","LU0540923850.HKD","LU2399975544.HKD","BK1574","LU0348783233.USD"],"gpt_icon":0},{"id":"2581886538","title":"Summit Therapeutics Reports Ivonescimab Plus Chemotherapy Improves Survival in EGFR-Mutated NSCLC Phase III Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2581886538","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581886538?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:01","pubTimestamp":1762524068,"startTime":"0","endTime":"0","summary":"Summit Therapeutics Inc. announced that results from the Phase III HARMONi-A clinical trial, conducted by its partner Akeso, Inc. in China, have been presented at the Annual Meeting of the Society for Immunotherapy of Cancer . The trial evaluated the investigational bispecific antibody ivonescimab in combination with chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer  who had previously received a third-generation EGFR TKI. The study demonstrated a statistically significant benefit in overall survival, with a reported hazard ratio of 0.74. The safety profile of ivonescimab in combination with chemotherapy was described as manageable. In May 2024, Akeso announced the approval of ivonescimab plus chemotherapy in this treatment setting in China, following the HARMONi-A trial results. An administrative review of overall survival at 52% data maturity reported a hazard ratio of 0.80  with a data cutoff in December 2023.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL8MRSy6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348766576.USD","LU0417516902.SGD","09926","IE00B5MMRT66.SGD","LU0348767384.USD","LU0417516571.SGD","BK1161","BK4139","LU0634319403.HKD","LU2476274308.USD","LU0540923850.HKD","IE00B543WZ88.USD","LU0348825331.USD","LU0348783233.USD","LU1794554557.SGD","LU0561508036.HKD","LU1961090484.USD","IE00BPRC5H50.USD","LU2399975544.HKD","LU2476274720.SGD","LU2488822045.USD","LU1720050803.USD","LU2778985437.USD","LU0417516738.SGD","BK1574","LU0348784397.USD","LU0348735423.USD","LU0348827113.USD","SMMT"],"gpt_icon":0},{"id":"1186694095","title":"Orient Securities: First Commercial Insurance Drug List Introduced, Policy Support for Innovative Drugs Becomes Clearer","url":"https://stock-news.laohu8.com/highlight/detail?id=1186694095","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186694095?lang=en_us&edition=fundamental","pubTime":"2025-11-07 14:40","pubTimestamp":1762497627,"startTime":"0","endTime":"0","summary":"Orient Securities released a research report stating that the introduction of a commercial insurance drug list for innovative medicines is expected to leverage market forces to address the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03958","06990","00013","LU0348735423.USD","159992","LU2476274720.SGD","LU1961090484.USD","BK0028","BK0012","BK1587","LU0348766576.USD","LU0540923850.HKD","LU2778985437.USD","LU0634319403.HKD","LU0196878994.USD","BK0276","BK0183","LU0417516902.SGD","06978","BK1191","BK0188","LU0348784397.USD","600958","LU0561508036.HKD","LU2399975544.HKD","BK1147","LU1794554557.SGD","IE00B543WZ88.USD","LU0348825331.USD","BK1588","BK1574","LU0348783233.USD","LU0417516738.SGD","09926","LU0417516571.SGD","LU2488822045.USD","LU1720050803.USD","BK1564","LU2476274308.USD","LU0348827113.USD","IE00B5MMRT66.SGD","BK1161","LU0348767384.USD","IE00BPRC5H50.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akesobio.com","stockEarnings":[{"period":"1week","weight":0.0098},{"period":"1month","weight":0.0886},{"period":"3month","weight":-0.1978},{"period":"6month","weight":0.5088},{"period":"1year","weight":0.8961},{"period":"ytd","weight":1.0445}],"compareEarnings":[{"period":"1week","weight":0.0087},{"period":"1month","weight":0.0058},{"period":"3month","weight":0.0262},{"period":"6month","weight":0.0964},{"period":"1year","weight":0.3336},{"period":"ytd","weight":0.3004}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Akeso Inc is an investment holding company dedicated to the research, development, manufacturing and commercialization of antibody drugs that are affordable to patients worldwide. The Company’s programs covering the therapeutic areas of oncology, autoimmune and metabolic diseases. The Company's products mainly include cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), Ligufalimab (AK117, CD47), Pulocimab (AK109, VEGFR-2), ANNIKO (penpulimab, PD-1), and tagitanlimab (PD-L1) used in oncology fields as well as ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), and Gumokimab (AK111, IL-17) used in metabolic and autoimmune therapeutic fields.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.000596},{"month":2,"riseRate":0.4,"avgChangeRate":0.029178},{"month":3,"riseRate":0.4,"avgChangeRate":-0.035342},{"month":4,"riseRate":0.8,"avgChangeRate":0.041218},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.003133},{"month":6,"riseRate":0.666667,"avgChangeRate":0.133235},{"month":7,"riseRate":0.5,"avgChangeRate":0.087867},{"month":8,"riseRate":0.5,"avgChangeRate":-0.007754},{"month":9,"riseRate":0.5,"avgChangeRate":0.036209},{"month":10,"riseRate":0.5,"avgChangeRate":0.046029},{"month":11,"riseRate":1,"avgChangeRate":0.102206},{"month":12,"riseRate":0.5,"avgChangeRate":0.043332}],"exchange":"SEHK","name":"AKESO","nameEN":"AKESO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AKESO(09926),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest AKESO(09926) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"AKESO,09926,AKESO股票,AKESO股票老虎,AKESO股票老虎国际,AKESO行情,AKESO股票行情,AKESO股价,AKESO股市,AKESO股票价格,AKESO股票交易,AKESO股票购买,AKESO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AKESO(09926),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest AKESO(09926) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}